Full text is available at the source.
Abstract
Incretin-based therapies, including GLP-1 receptor agonists and dual receptor agonists, are increasingly utilized for managing hyperglycaemia and obesity.
- These therapies target cardiometabolic disorders such as type 2 diabetes, obesity, and cardiovascular disease.
- Semaglutide and liraglutide are examples of GLP-1 receptor agonists used in treatment.
- Tirzepatide acts as a dual GIP/GLP-1 receptor agonist.
- The therapies have been evaluated for their effects on cardiometabolic risk markers.
- They are also assessed for selected cardiovascular and renal outcomes.
Simplified